IMMUTEP LIMITED - Announcements

3.57%

27.0¢

Market Cap $396.3M

Healthcare Biotechnology

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

IMM	Proposed issue of Securities - IMM		29/04/20	25.51KB	Share
IMM	Immutep Investor Presentation	PRICE SENSITIVE	29/04/20	2.12MB	Share
IMM	Immutep completes A$12 million placement	PRICE SENSITIVE	29/04/20	302.81KB	Share
IMM	Immutep Reports Positive Phase II TACTI-002 Data	PRICE SENSITIVE	28/04/20	387.29KB	Share
IMM	Trading Halt	PRICE SENSITIVE	27/04/20	265.26KB	Share
IMM	Enrollment completed for the INSIGHT-004 Study	PRICE SENSITIVE	22/04/20	237.88KB	Share
IMM	Immutep March Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	20/04/20	433.73KB	Share
IMM	Immutep advances its LAG-3 agonist for autoimmune diseases	PRICE SENSITIVE	16/04/20	299.3KB	Share
IMM	Immutep presents TACTI-002 data at AACR Virtual Meeting	PRICE SENSITIVE	14/04/20	246.66KB	Share
IMM	EOC Pharma confirms plans to advance Efti in China for MBC	PRICE SENSITIVE	08/04/20	255.3KB	Share
IMM	Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides	PRICE SENSITIVE	26/03/20	979.72KB	Share
IMM	Immutep reports supportive efficacy data from AIPAC study	PRICE SENSITIVE	25/03/20	283.61KB	Share
IMM	Immutep's Partner, EOC completes recruitment of Phase 1		20/03/20	265.76KB	Share
IMM	Change of Director's Interest Notice - Mr Chamberlain		16/03/20	195.38KB	Share
IMM	Immutep receives 2nd IND approval for efti from US FDA	PRICE SENSITIVE	09/03/20	255.32KB	Share
IMM	Change in substantial holding		02/03/20	248.97KB	Share
IMM	Immutep Clinical Update & Results Global Webcast Slides		25/02/20	1.08MB	Share
IMM	Change in substantial holding		21/02/20	245.3KB	Share
IMM	Half Yearly Report and Accounts	PRICE SENSITIVE	21/02/20	779.6KB	Share
IMM	Immutep reports positive TACTI-002 data	PRICE SENSITIVE	19/02/20	372.43KB	Share
IMM	Change in substantial holding		05/02/20	230.49KB	Share
IMM	Immutep to present TACTI-002 data at German Cancer Congress		04/02/20	271.82KB	Share
IMM	Immutep Activities Report	PRICE SENSITIVE	29/01/20	243.88KB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/20	185.6KB	Share
IMM	Immutep Corporate Presentation		10/01/20	1.44MB	Share
IMM	Immutep expands Part C of TACTI-002 due to positive data	PRICE SENSITIVE	09/01/20	255.17KB	Share
IMM	Change in substantial holding		06/01/20	258.08KB	Share
IMM	Change of Director's Interest Notice		02/01/20	191.84KB	Share
IMM	Appendix 3B		02/01/20	501.39KB	Share
IMM	INSIGHT-004 clinical trial update	PRICE SENSITIVE	19/12/19	268.57KB	Share
IMM	Change of Director's Interest Notice - Mr Meyers		09/12/19	195.96KB	Share
IMM	Change of Director's Interest Notice - Dr Howard		09/12/19	186.22KB	Share
IMM	Change of Director's Interest Notice - Mr Voigt		09/12/19	187.15KB	Share
IMM	Appendix 3B		02/12/19	552.38KB	Share
IMM	Immutep Investor Update		22/11/19	2.5MB	Share
IMM	Immutep announces European patent grant for LAG525 antibody	PRICE SENSITIVE	14/11/19	222.42KB	Share
IMM	IMM presents positive interim phase 2 TACTI-002 data at SITC	PRICE SENSITIVE	08/11/19	313.67KB	Share
IMM	Update - Consolidation/Split - IMM		01/11/19	34.84KB	Share
IMM	Results of Annual General Meeting		01/11/19	209.7KB	Share
IMM	2019 AGM CEO Presentation		01/11/19	1.03MB	Share
IMM	2019 AGM Chairman's Address		01/11/19	212.2KB	Share
IMM	Consolidation/Split - IMM		31/10/19	34.73KB	Share
IMM	Operational Update	PRICE SENSITIVE	28/10/19	304.46KB	Share
IMM	Change in substantial holding		24/10/19	266.95KB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	23/10/19	164.66KB	Share
IMM	Immutep presents positive TACTI-mel melanoma trial data	PRICE SENSITIVE	15/10/19	2.5MB	Share
IMM	Immutep receives A$2.5M R&D French Tax Incentive	PRICE SENSITIVE	10/10/19	257.96KB	Share
IMM	Immutep to present data at upcoming Industry Conferences		10/10/19	231.99KB	Share
IMM	Change of Director's Interest Notice - Mr Chamberlain		04/10/19	197.37KB	Share
IMM	Change of Director's Interest Notice - Mr Meyers		04/10/19	195.79KB	Share
IMM	Appendix 3B		03/10/19	468.71KB	Share
IMM	Immutep Investor Presentation		30/09/19	2.16MB	Share
IMM	Notice of Annual General Meeting/Proxy Form		30/09/19	904.71KB	Share
IMM	Appendix 4G & Corporate Governance Statement		30/09/19	376.93KB	Share
IMM	Annual Report to shareholders		30/09/19	1.11MB	Share
IMM	Immutep expands Part A of TACTI-002 due to positive data	PRICE SENSITIVE	26/09/19	266KB	Share
IMM	Annual Report filed on Form 20-F with SEC		24/09/19	961.08KB	Share
IMM	Immutep to receive GBP4M Milestone Payment from GSK	PRICE SENSITIVE	23/09/19	231.92KB	Share
IMM	Japanese patent granted for LAG525 antibody	PRICE SENSITIVE	17/09/19	224.71KB	Share
IMM	Immutep granted European patent for IMP321 in cancer	PRICE SENSITIVE	22/08/19	222.26KB	Share
IMM	Appendix 4E & 2019 Full Year Statutory Accounts	PRICE SENSITIVE	20/08/19	1.22MB	Share
IMM	Ceasing to be a substantial holder from AEF		13/08/19	155.46KB	Share
IMM	Change in substantial holding		09/08/19	189.91KB	Share
IMM	Change of Director's Interest Notice - Mr Chamberlain		07/08/19	195.07KB	Share
IMM	Change of Director's Interest Notice - Mr Voigt		07/08/19	190.83KB	Share
IMM	Immutep completes fully underwritten A$6M Entitlement Offer		06/08/19	275.64KB	Share
IMM	Entitlement Offer Results & Shortfall Notification	PRICE SENSITIVE	01/08/19	214.7KB	Share
IMM	Operational Update	PRICE SENSITIVE	26/07/19	309.99KB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	26/07/19	200.12KB	Share
IMM	Becoming a substantial holder from AEF		19/07/19	109.82KB	Share
IMM	Change in substantial holding		19/07/19	319.22KB	Share
IMM	Mailing of Offer Booklet for Entitlement Offer		17/07/19	69.75KB	Share
IMM	Cleansing Notice		17/07/19	119.86KB	Share
IMM	Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b)		17/07/19	163.61KB	Share
IMM	Cleansing Notice		09/07/19	133.99KB	Share
IMM	Letter to Ineligible Shareholders		09/07/19	175.34KB	Share
IMM	Letter to Eligible Shareholders		09/07/19	195.53KB	Share
IMM	Appendix 3B		09/07/19	428.02KB	Share
IMM	Immutep Entitlement Offer Booklet	PRICE SENSITIVE	09/07/19	2.2MB	Share
IMM	Immutep Capital Raising Presentation	PRICE SENSITIVE	09/07/19	1.9MB	Share
IMM	Immutep raises A$10M via placement & entitlement offer	PRICE SENSITIVE	09/07/19	354.6KB	Share
IMM	Trading Halt	PRICE SENSITIVE	05/07/19	404.39KB	Share
IMM	Immutep completes recruitment of AIPAC trial in MBC	PRICE SENSITIVE	25/06/19	273.56KB	Share
IMM	Immutep hosts Key Opinion Leader Call		25/06/19	232.6KB	Share
IMM	Immutep granted Australian patent for eftilagimod alpha	PRICE SENSITIVE	21/06/19	176.25KB	Share
IMM	Immutep completes recruitment of initial NSCLC cohort	PRICE SENSITIVE	13/06/19	261.66KB	Share
IMM	First patient dosed in INSIGHT-004	PRICE SENSITIVE	06/06/19	272.1KB	Share
IMM	Appendix 3B		03/06/19	583.76KB	Share
IMM	Immutep Poster Presentation at ASCO		03/06/19	260.28KB	Share
IMM	Immutep granted European patent for eftilagimod alpha	PRICE SENSITIVE	23/05/19	221.36KB	Share
IMM	More mature positive data for TACTI-mel trial presented	PRICE SENSITIVE	17/05/19	229.17KB	Share
IMM	Immutep to present at upcoming industry conferences		10/05/19	233KB	Share
IMM	Becoming a substantial holder		08/05/19	2.76MB	Share
IMM	Operational Update	PRICE SENSITIVE	30/04/19	307.42KB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/19	199.85KB	Share
IMM	Webcast slides for eftilagimod alpha (IMP321)		02/04/19	1.36MB	Share
IMM	Webcast details for update on eftilagimod alpha (IMP321)		27/03/19	251.64KB	Share
IMM	Ceasing to be a substantial holder		26/03/19	271.05KB	Share
IMM	IMP761 Webcast Slides		25/03/19	831.16KB	Share
IMM	Immutep granted US patent for IMP321	PRICE SENSITIVE	22/03/19	177.28KB	Share

IMM Proposed issue of Securities - IMM
29/04/20		25.51KB	Share
IMM Immutep Investor Presentation
29/04/20	PRICE SENSITIVE	2.12MB	Share
IMM Immutep completes A$12 million placement
29/04/20	PRICE SENSITIVE	302.81KB	Share
IMM Immutep Reports Positive Phase II TACTI-002 Data
28/04/20	PRICE SENSITIVE	387.29KB	Share
IMM Trading Halt
27/04/20	PRICE SENSITIVE	265.26KB	Share
IMM Enrollment completed for the INSIGHT-004 Study
22/04/20	PRICE SENSITIVE	237.88KB	Share
IMM Immutep March Quarterly Activities Report & Appendix 4C
20/04/20	PRICE SENSITIVE	433.73KB	Share
IMM Immutep advances its LAG-3 agonist for autoimmune diseases
16/04/20	PRICE SENSITIVE	299.3KB	Share
IMM Immutep presents TACTI-002 data at AACR Virtual Meeting
14/04/20	PRICE SENSITIVE	246.66KB	Share
IMM EOC Pharma confirms plans to advance Efti in China for MBC
08/04/20	PRICE SENSITIVE	255.3KB	Share
IMM Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides
26/03/20	PRICE SENSITIVE	979.72KB	Share
IMM Immutep reports supportive efficacy data from AIPAC study
25/03/20	PRICE SENSITIVE	283.61KB	Share
IMM Immutep's Partner, EOC completes recruitment of Phase 1
20/03/20		265.76KB	Share
IMM Change of Director's Interest Notice - Mr Chamberlain
16/03/20		195.38KB	Share
IMM Immutep receives 2nd IND approval for efti from US FDA
09/03/20	PRICE SENSITIVE	255.32KB	Share
IMM Change in substantial holding
02/03/20		248.97KB	Share
IMM Immutep Clinical Update & Results Global Webcast Slides
25/02/20		1.08MB	Share
IMM Change in substantial holding
21/02/20		245.3KB	Share
IMM Half Yearly Report and Accounts
21/02/20	PRICE SENSITIVE	779.6KB	Share
IMM Immutep reports positive TACTI-002 data
19/02/20	PRICE SENSITIVE	372.43KB	Share
IMM Change in substantial holding
05/02/20		230.49KB	Share
IMM Immutep to present TACTI-002 data at German Cancer Congress
04/02/20		271.82KB	Share
IMM Immutep Activities Report
29/01/20	PRICE SENSITIVE	243.88KB	Share
IMM Appendix 4C - quarterly
29/01/20	PRICE SENSITIVE	185.6KB	Share
IMM Immutep Corporate Presentation
10/01/20		1.44MB	Share
IMM Immutep expands Part C of TACTI-002 due to positive data
09/01/20	PRICE SENSITIVE	255.17KB	Share
IMM Change in substantial holding
06/01/20		258.08KB	Share
IMM Change of Director's Interest Notice
02/01/20		191.84KB	Share
IMM Appendix 3B
02/01/20		501.39KB	Share
IMM INSIGHT-004 clinical trial update
19/12/19	PRICE SENSITIVE	268.57KB	Share
IMM Change of Director's Interest Notice - Mr Meyers
09/12/19		195.96KB	Share
IMM Change of Director's Interest Notice - Dr Howard
09/12/19		186.22KB	Share
IMM Change of Director's Interest Notice - Mr Voigt
09/12/19		187.15KB	Share
IMM Appendix 3B
02/12/19		552.38KB	Share
IMM Immutep Investor Update
22/11/19		2.5MB	Share
IMM Immutep announces European patent grant for LAG525 antibody
14/11/19	PRICE SENSITIVE	222.42KB	Share
IMM IMM presents positive interim phase 2 TACTI-002 data at SITC
08/11/19	PRICE SENSITIVE	313.67KB	Share
IMM Update - Consolidation/Split - IMM
01/11/19		34.84KB	Share
IMM Results of Annual General Meeting
01/11/19		209.7KB	Share
IMM 2019 AGM CEO Presentation
01/11/19		1.03MB	Share
IMM 2019 AGM Chairman's Address
01/11/19		212.2KB	Share
IMM Consolidation/Split - IMM
31/10/19		34.73KB	Share
IMM Operational Update
28/10/19	PRICE SENSITIVE	304.46KB	Share
IMM Change in substantial holding
24/10/19		266.95KB	Share
IMM Appendix 4C - quarterly
23/10/19	PRICE SENSITIVE	164.66KB	Share
IMM Immutep presents positive TACTI-mel melanoma trial data
15/10/19	PRICE SENSITIVE	2.5MB	Share
IMM Immutep receives A$2.5M R&D French Tax Incentive
10/10/19	PRICE SENSITIVE	257.96KB	Share
IMM Immutep to present data at upcoming Industry Conferences
10/10/19		231.99KB	Share
IMM Change of Director's Interest Notice - Mr Chamberlain
04/10/19		197.37KB	Share
IMM Change of Director's Interest Notice - Mr Meyers
04/10/19		195.79KB	Share
IMM Appendix 3B
03/10/19		468.71KB	Share
IMM Immutep Investor Presentation
30/09/19		2.16MB	Share
IMM Notice of Annual General Meeting/Proxy Form
30/09/19		904.71KB	Share
IMM Appendix 4G & Corporate Governance Statement
30/09/19		376.93KB	Share
IMM Annual Report to shareholders
30/09/19		1.11MB	Share
IMM Immutep expands Part A of TACTI-002 due to positive data
26/09/19	PRICE SENSITIVE	266KB	Share
IMM Annual Report filed on Form 20-F with SEC
24/09/19		961.08KB	Share
IMM Immutep to receive GBP4M Milestone Payment from GSK
23/09/19	PRICE SENSITIVE	231.92KB	Share
IMM Japanese patent granted for LAG525 antibody
17/09/19	PRICE SENSITIVE	224.71KB	Share
IMM Immutep granted European patent for IMP321 in cancer
22/08/19	PRICE SENSITIVE	222.26KB	Share
IMM Appendix 4E & 2019 Full Year Statutory Accounts
20/08/19	PRICE SENSITIVE	1.22MB	Share
IMM Ceasing to be a substantial holder from AEF
13/08/19		155.46KB	Share
IMM Change in substantial holding
09/08/19		189.91KB	Share
IMM Change of Director's Interest Notice - Mr Chamberlain
07/08/19		195.07KB	Share
IMM Change of Director's Interest Notice - Mr Voigt
07/08/19		190.83KB	Share
IMM Immutep completes fully underwritten A$6M Entitlement Offer
06/08/19		275.64KB	Share
IMM Entitlement Offer Results & Shortfall Notification
01/08/19	PRICE SENSITIVE	214.7KB	Share
IMM Operational Update
26/07/19	PRICE SENSITIVE	309.99KB	Share
IMM Appendix 4C - quarterly
26/07/19	PRICE SENSITIVE	200.12KB	Share
IMM Becoming a substantial holder from AEF
19/07/19		109.82KB	Share
IMM Change in substantial holding
19/07/19		319.22KB	Share
IMM Mailing of Offer Booklet for Entitlement Offer
17/07/19		69.75KB	Share
IMM Cleansing Notice
17/07/19		119.86KB	Share
IMM Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b)
17/07/19		163.61KB	Share
IMM Cleansing Notice
09/07/19		133.99KB	Share
IMM Letter to Ineligible Shareholders
09/07/19		175.34KB	Share
IMM Letter to Eligible Shareholders
09/07/19		195.53KB	Share
IMM Appendix 3B
09/07/19		428.02KB	Share
IMM Immutep Entitlement Offer Booklet
09/07/19	PRICE SENSITIVE	2.2MB	Share
IMM Immutep Capital Raising Presentation
09/07/19	PRICE SENSITIVE	1.9MB	Share
IMM Immutep raises A$10M via placement & entitlement offer
09/07/19	PRICE SENSITIVE	354.6KB	Share
IMM Trading Halt
05/07/19	PRICE SENSITIVE	404.39KB	Share
IMM Immutep completes recruitment of AIPAC trial in MBC
25/06/19	PRICE SENSITIVE	273.56KB	Share
IMM Immutep hosts Key Opinion Leader Call
25/06/19		232.6KB	Share
IMM Immutep granted Australian patent for eftilagimod alpha
21/06/19	PRICE SENSITIVE	176.25KB	Share
IMM Immutep completes recruitment of initial NSCLC cohort
13/06/19	PRICE SENSITIVE	261.66KB	Share
IMM First patient dosed in INSIGHT-004
06/06/19	PRICE SENSITIVE	272.1KB	Share
IMM Appendix 3B
03/06/19		583.76KB	Share
IMM Immutep Poster Presentation at ASCO
03/06/19		260.28KB	Share
IMM Immutep granted European patent for eftilagimod alpha
23/05/19	PRICE SENSITIVE	221.36KB	Share
IMM More mature positive data for TACTI-mel trial presented
17/05/19	PRICE SENSITIVE	229.17KB	Share
IMM Immutep to present at upcoming industry conferences
10/05/19		233KB	Share
IMM Becoming a substantial holder
08/05/19		2.76MB	Share
IMM Operational Update
30/04/19	PRICE SENSITIVE	307.42KB	Share
IMM Appendix 4C - quarterly
24/04/19	PRICE SENSITIVE	199.85KB	Share
IMM Webcast slides for eftilagimod alpha (IMP321)
02/04/19		1.36MB	Share
IMM Webcast details for update on eftilagimod alpha (IMP321)
27/03/19		251.64KB	Share
IMM Ceasing to be a substantial holder
26/03/19		271.05KB	Share
IMM IMP761 Webcast Slides
25/03/19		831.16KB	Share
IMM Immutep granted US patent for IMP321
22/03/19	PRICE SENSITIVE	177.28KB	Share

REFRESH

First 4 5 6 7 8

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 27.0¢		Change -0.010(3.57%)		Mkt cap ! $396.3M

Open	High	Low	Value	Volume
28.0¢	28.3¢	27.0¢	$466.6K	1.692M

Buyers (Bids)

No.	Vol.	Price($)
7	448593	27.0¢

Sellers (Offers)

Price($)	Vol.	No.
27.5¢	150259	4

View Market Depth

No.	Vol.	Price($)
3	147410	0.270
8	354090	0.265
6	263758	0.260
13	567094	0.255
12	214290	0.250

Price($)	Vol.	No.
0.275	36000	1
0.280	643469	5
0.285	366793	10
0.290	434500	7
0.295	109151	4

Last trade - 16.10pm 08/08/2025 (20 minute delay)

IMM (ASX) Chart

IMMUTEP LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available